Cabozantinib and Nivolumab for Carcinoid Tumors

Neuroendocrine Tumors Clinical Trial

Official title: Phase II Trial of Cabozantinib in Combination With Nivolumab for Advanced Carcinoid Tumors

Status Completed

Clinical Trial Summary

This research study, is studying the combination of cabozantinib and nivolumab in treating advanced carcinoid tumors.

• Carcinoid tumor is another term used to refer to neuroendocrine tumors that arise in organs such as the gastrointestinal tract, lungs, or thymus.

Clinical Trial Description

This is open-label, single-arm, phase II research study, studying the combination of cabozantinib and nivolumab in treating advanced carcinoid tumors. Carcinoid tumor is another term used to refer to neuroendocrine tumors that arise in organs such as the gastrointestinal tract, lungs, or thymus.

• The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.

• Cabozantinib will be administered orally, once daily

• Nivolumab will be administered intravenously, every two weeks

• The target enrollment for this study is 35 participants.

• The U.S. Food and Drug Administration (FDA) has not approved cabozantinib or nivolumab for treating carcinoid tumors. ;

Related Conditions & MeSH terms

• Carcinoid Tumor
• Carcinoid Tumor of GI System
• Digestive System Neoplasms
• Gastrointestinal Neoplasms
• Neoplasms
• Neuroendocrine Tumors

• NCT number: NCT04197310
• Study type: Interventional
• Source: Dana-Farber Cancer Institute
• Status: Completed
• Phase: Phase 2
• Start date: December 26, 2019
• Completion date: January 31, 2024